PuriCore specializes in developing and commercializing solutions to protect against the spread of infectious pathogens. Our proprietary products are effective while being completely safe for human and animal health and the environment.

PuriCore has broad experience in key markets that depend upon effective pathogen control.
We are the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals.
We are the standard for protecting consumers and employees from contaminated fresh perishables in leading US supermarket chains.
We offer a safe and effective wound therapy solution to cleanse chronic and acute wounds including diabetic ulcers and burns.


http://www.puricore.com/

Final Results


FINANCIAL HIGHLIGHTS

· Group revenue up 15.6% (16.3% at constant currency) to $54.8m (2012: $47.4m), primarily due to strong performance in the Supermarket Retail business

§ Supermarket Retail revenue up 30.2% to $28.9m (2012: $22.2m)

§ Endoscopy revenue down 0.8% (up 0.5% at constant currency) to $23.3m (2012: $23.5m)

§ Wound Care and Dermatology revenue up 53.0% to $2.6m (2012: $1.7m)

· EBITDA* nearly doubled to $2.4m (2012: $1.3m)

· Gross profit margin decreased slightly to 32.4% (2012: 32.7%)

· Operating expenses increased to $18.5m (2012: $17.5m)

· Loss before interest and taxes reduced to $0.7m (2012: $2.1m)

· Cash flow generated from operating activities $1.5m (2012: $4.3m)

· Significantly strengthened balance sheet

§ Cash and cash equivalents of $3.4m (2012: $2.5m)

§ Extinguished convertible loan of £7.95m

§ Raised £2.3m (before expenses) in placing in January

§ No loans or borrowings ($13.4m as at 31 December 2012)



OPERATIONAL HIGHLIGHTS

Food & Agriculture

· Supermarket Retail: signed a major capital equipment sale and implemented three recurring revenue deals

§ Completed nearly all installations of a $14.0m Sterilox® Fresh order for a top-five US supermarket retailer

§ Initiated shipments of an estimated $13.5m, four-year agreement with a top-three US supermarket retailer for new ProduceFresh™ bottled concentrate

§ Completed implementation of an estimated $7.0m, four-year FloraFresh™ agreement with a top-three US supermarket retailer

§ Initiated shipments of an estimated $3.5m, four-year FloraFresh agreement with a leading US supermarket retailer





http://www.moneyam.com/action/news/showArticle?id=4797287

Share price getting hammered today on no news.

Interim Management Statement

RNS


RNS Number : 0591H

PuriCore Plc

14 May 2014






PuriCore plc: Interim Management Statement



14 May 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces its Interim Management Statement for the period from 1 January 2014 to 13 May 2014, which incorporates information in relation to the financial performance of the business for the first quarter being from 1 January 2014 to 31 March 2014.



Revenue for the Group decreased 2.9% to $10.6 million (6.4% at constant currency) in the first quarter of 2014 (Q1 2013: $10.9 million), as higher recurring revenues were offset by delays in capital orders. Cash and cash equivalents were $3.9 million as at 31 March 2014 (as at 31 December 2013: $3.4 million).



Food & Agriculture

In the Supermarket Retail business, revenue increased 17.8% to $4.3 million (Q1 2013: $3.6 million) due to growth in the Company's concentrate products. During the period, this business completed all remaining Sterilox Fresh System installations for the $14.0 million agreement with a top-five US supermarket retailer announced in April last year as well as continued shipments of FloraFresh and ProduceFresh bottled concentrate products under the three major multi-year contracts with leading US retailers. For the full year, the Supermarket Retail business plans to invest in sales and marketing to drive growth in product usage of FloraFresh and ProduceFresh as well as to expand the Floral business target market to florists and into the floral supply chain.



Health Sciences

During the first quarter of 2014, Endoscopy revenue decreased 6.0% (12.0% at constant currency) to $5.9 million (Q1 2013: $6.2 million). The decrease was due to delays in capital orders and planned heavier sales in the second half of the year in anticipation of the launch of the new state-of-the-art endoscope washer disinfector, RapidAER®. During the quarter, the Endoscopy business completed final testing of and received CE marking for the new product. Market acceptance of RapidAER has been favourable, and sales orders are already in hand with shipments planned to commence in June.



Global Wound Care and Dermatology revenue decreased 55.8% to $0.5 million (Q1 2013: $1.1 million) primarily due to a significant portion of the prior period's revenue comprising milestone payments. PuriCore signed a marketing and distribution agreement with Ueno Corporation for Vashe in 15 Middle East and North African countries in February 2014. Initial shipments to Ueno commenced in the first quarter of 2014. In April 2014, PuriCore launched a complementary product for the Animal Health market, NovaZo Wound Hydrogel Dressing.



Michael Ashton, Executive Chairman, said:

"During the quarter, we further advanced our multi-year strategy that focuses on increasing recurring revenue through new products and partnerships. We experienced a slight decrease in revenue for the period driven by higher recurring revenues offset by delays in capital orders, due in part to hospitals awaiting availability of our new RapidAER. For the remainder of 2014, we will invest strategically in our Supermarket Retail business to drive growth and aim to increase revenue in the UK Endoscopy business driven through new product launches and ancillary recurring revenue streams. The new Middle Eastern partnership, plus other international partnerships being pursued in all business areas, offers opportunities to leverage marketing resources whilst delivering growth."

Good recovery this week.

And this week.

Getting back to its highs

Sale of Endoscopy Business

RNS


RNS Number : 7958I

PuriCore Plc

04 June 2014








PuriCore plc

("PuriCore" or the "Company")



Sale of Endoscopy Business



4 June 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces that it has conditionally agreed to sell the entire issued share capital of PuriCore International Limited, the Company's UK Endoscopy business, to Medivators B.V. for $26.9 million in cash.



· Sale of the Company's UK Endoscopy business for $26.9 million (gross) payable in cash on Completion (subject to Adjustments).



· Medivators B.V., a European-based subsidiary of Cantel Medical Corp. (NYSE: CMN), is a leading provider of infection prevention and control products and services in the healthcare market.



· The Company has initiated a comprehensive strategic review of the business to determine the best use of proceeds, which are expected to be approximately $25.3 million. This includes enhanced investment in the Continuing Businesses, potential strategic acquisitions in complementary businesses, and/or a potential return to shareholders.



· During the financial year ended 31 December 2013, PuriCore International Limited generated revenue of $23.3 million, with profit before tax of $2.1 million.



· Subject to Shareholder approval at the General Meeting to be held on 20 June 2014 and other conditions, it is currently anticipated that the sale will be completed on 30 June 2014.



· Shareholder approval must be obtained from more than 50 per cent. of the votes cast. Irrevocable undertakings and a non-binding letter of intent in support of the transaction have been received in respect of an aggregate of 28,902,389 Ordinary Shares representing 57.65 per cent. of the Issued Ordinary Share Capital.



Michael Ashton, Executive Chairman, said:

"The Board sees the greatest prospects for future sustainable growth of the Company through targeted expansion of our businesses in the Supermarket Retail and the Health Sciences segments. There are a number of options under consideration which include further leveraging of our core proprietary hypochlorous technology and strategic acquisitions that complement our existing businesses in these segments. We are currently engaged in a comprehensive strategic review to evaluate these opportunities.



"Against this backdrop we are delighted to announce this proposed cash sale of the Endoscopy business that will provide us with the resources to accelerate our strategic plans. Whilst the UK-based Endoscopy business has successfully evolved to supply products and services to hospitals in the UK, the vast majority of these do not rely on ourcore intellectual property and, as such, lack synergies with those in our other segments.



"The Board would like to thank our UK team for their work and dedication to PuriCore over the years and we wish them and the business much future success

Trading Update and Strategic Review

RNS


RNS Number : 0360M

PuriCore Plc

11 July 2014






Trading Update and Strategic Review



11 July 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today issues an update on trading ahead of the publication of its results for the six months ended 30 June 2014, which is expected during the week of 4 August 2014, as well as an update on the initiation of a strategic review to determine the next phase in the Company's development.



Trading Update

With the sale of the Endoscopy business now successfully completed, PuriCore is focusing additional resources on the adoption and rollout of bottled Supermarket Retail concentrate products, ProduceFresh® and FloraFresh®, as its key operational priority. As previously reported, with the rebalancing of the product mix, the Company is experiencing a reduction in revenue in this business in the near term as customers transition to consumable products and capital equipment sales decline. In-market demand for consumable implementations has been encouragingly strong with existing and new customers signing on for the new products. Meeting this demand in a short timeframe has resulted in higher than expected service costs during the period, which is being addressed as an operational priority. The Board remains confident that with enhanced investment in sales and marketing resources, accelerated market share can continue to be achieved.



Further, the trends reported in Health Sciences in the Q1 Interim Management Statement continued into Q2. With the distraction of the Endoscopy business sale process and the delay in capital sales preceding the launch of the new endoscope washer disinfector, earnings in H1 are expected to be lower than in prior year H1. The Wound Care and Dermatology business showed progress in H1, but with the absence of comparable milestone payments as were booked in H1 2013, revenues and earnings are expected to be softer.



As a result of all these factors, the Company expects to report an operational EBITDA* loss for H1 2014, materially lower than the positive EBITDA reported for H1 2013. Full results, including the financial impact of the sale of the Endoscopy business, will be provided in the interims to be released in early August.



Strategic Review

Meanwhile, the Board has initiated a strategic and operational review of the business to optimise the use of the proceeds from the sale of the Endoscopy business to build shareholder value. This review covers growth investment strategies, operational efficiency initiatives, R&D programmes, strategic acquisitions, and a potential return to shareholders. The Company will continue to focus on tight cost control to optimise margins whilst recognising that growth initiatives will require further investment in key areas. Following review and approval by the Board, the strategic plan will be communicated to shareholders in Q4 2014, along with revised expectations of full-year performance.



The Board believes sustainable growth should be driven by increasing recurring revenues in both continuing businesses. The Company has therefore identified the following key areas of strategic focus within these businesses for further investment and potential complementary acquisitions.



Supermarket Retail

· Identify additional investment opportunities to drive rapid adoption of ProduceFresh and FloraFresh

· Extend the footprint with supermarket customers by delivering novel product formats in new areas within the store



Wound Care and Dermatology

· Develop opportunities to expand the product portfolio, formats, and geographic reach

· Invest in clinical studies to support both infection control regulatory approvals and wider marketing initiatives



Michael Ashton, Chief Executive Officer, said:

"The sale of the Endoscopy business opens a new chapter for PuriCore. Whilst we faced some disruption in the first half as a result of selling the UK business, transitioning away from a capital-intensive business in Supermarket Retail, and meeting demand for our new concentrate products, we continue to see opportunities for sustainable growth within and around our refocused businesses. Our strengthened cash position provides us with the resources and confidence to optimise these opportunities through investment in a targeted and disciplined manner. We look forward to sharing our new strategic plan together with our revised expectations for current year results in the autumn."



* Earnings before interest, tax, depreciation, amortisation, and non-cash equity-related charges

12/08/2014 BUY Michael Ashton CEO 50,000
12/08/2014 BUY Michael Ashton CEO 100,000

Interim Management Statement

RNS


RNS Number : 7793V

PuriCore Plc

31 October 2014






PuriCore plc

Interim Management Statement

Strategic Review Update by Year End



31 October 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces its Interim Management Statement for the period from 1 July 2014 to 30 October 2014, which incorporates information in relation to the financial performance of the business for the third quarter and nine months ended 30 September 2014.



Group Results (Continuing Operations) *

Group revenue for the nine months ended 30 September 2014 decreased 39.5% to $13.2 million (2013: $21.9 million). In the third quarter of 2014, as expected, Group revenue decreased to $4.7 million (Q3 2013: $9.5 million). This reflects the impact of the continued rebalancing of Supermarket Retail product mix, as consumable product sales increase and capital equipment sales decline, in line with the fundamental change in the Supermarket Retail business model implemented last year.



Cash and cash equivalents, net of debt, were $22.7 million as at 30 September 2014. As at 1 July 2014, following receipt of PuriCore International Limited sale proceeds, pay-down of the line of credit, and payment of a limited portion of sale related expenses, gross cash and cash equivalents were $26.8 million.



Supermarket Retail Revenue

Revenue decreased 39.6% to $11.9 million for the nine months (2013: $19.8 million). However, during the period, new recurring revenue streamswere created by adding new customer stores and converting existing customer locations to ProduceFresh® as well as from new stores implementing FloraFresh®.



Wound Care and Dermatology Revenue

Revenue, excluding milestones payments, was constant at $1.3 million for the first nine months of 2014 (2013: $1.3 million, excluding $0.8 million of milestone payments). The Company is evaluating the performance of distributors in these markets and is seeking new partners to expand geographic reach.



Outlook

The Board remains confident in PuriCore's ability to deliver value to shareholders by leveraging its unique hypochlorous acid technology in markets and applications for which it delivers a competitive advantage. As expected, 2014 revenues and earnings will be lower than in the prior year as the business model in Supermarket Retail transitions and investments are made across the Group to support longer-term growth. The Company will remain vigilant in controlling costs and preserving cash while prudently investing for the future. The Board has advanced the strategic and operational review of the business and plans to announce further details later this year.



Michael Ashton, Chief Executive Officer of PuriCore, said:

"The lower reported revenue for the period is consistent with the announced change in the Supermarket Retail business, from a capital sales driven business model to one that will deliver more consistent recurring revenues. We are confident that this shift is the right strategy for the longer-term success of the business.



"Through the strategic review, we have identified new growth opportunities across the Group in which we will invest while implementing focused cost reduction plans elsewhere. These opportunities entail new products and applications as well as geographic expansion and centre on leveraging PuriCore's patented technology. As the strategy continues to evolve, we will share further updates with the market later this year."



* As previously announced, the Company completed the disposal of the UK Endoscopy business on 30 June 2014. Accordingly, the results of operations for that business, including the impact of the disposal, are reported as Discontinued Operations. The Continuing Operations comprise the Company's Supermarket Retail and Wound Care and Dermatology businesses. Group Results reflect the Continuing Operations only and the comparative prior period results have been re-stated to reflect only the Continuing Operations.

Puricore commences trading on AIM

RNS


RNS Number : 4394A

PuriCore Plc

23 December 2014






PuriCore plc

("PuriCore" or the "Company")



Puricore commences trading on AIM



23 December2014 - PuriCore plc (AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, is pleased to announce the admission of the Company's entire issued share capital comprising 50,135,432 ordinary shares of 10 pence each ("Ordinary Shares") to the AIM market of the London Stock Exchange. Trading in the Company's shares will begin at 8.00 a.m. today. PuriCore's Ordinary Shares have been removed from trading on the Main Market of the London Stock Exchange and their listing on the Official List has been cancelled. The Company's ticker remains PURI.



Information on PuriCore and its business, including that required by AIM Rule 26, can be found on the Company's website: www.puricore.com.

Signs Major Supermarket Deal
RNS
RNS Number : 8412H
PuriCore Plc
19 March 2015



PuriCore plc ("PuriCore" or the "Company")



Signs Major Supermarket Deal



Estimated $17.8 Million Sterilox® Fresh Agreement





19 March 2015 - PuriCore plc (AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, today announces it has signed a new Sterilox® Fresh agreement worth approximately $17.8 million over the next six years, with a top-three US supermarket retailer.



Over the past 18 months, the Company has expanded its product platforms to provide customers with flexible purchasing options for its proprietary food-safe sanitising solution that can be adapted to suit their business needs. Customers can now choose between the traditional capital equipment route, purchasing a Sterilox® Fresh System, which can be beneficial to high volume users, and ProduceFresh®, the concentrate product, which is a bottled consumable version supplied through a concentrate delivery system (CDS). PuriCore's strategy remains to establish increasing recurring revenue and a more predictable business, whilst providing the option for a capital equipment purchase to those customers for whom it is more suitable.



Under the terms of the agreement, the retailer will purchase the Sterilox Fresh Systems and an extended five-year warranty contract. Installation of the equipment will commence in late Q2 2015, with completion expected in Q1 2016 and the capital revenue, totalling approximately $11.4 million, will be recognised over this period. The recurringrevenue from the service agreement, totalling approximately $6.4 million, will be recognised over the term of the warranty, which extends into 2021.



As a high volume user of the solution, the customer in this agreement, currently using ProduceFresh, has decided to purchase capital equipment after determining that it is the most appropriate option for the majority of its enterprise. The CDSs already installed at the stores will remain in place and the customer will continue to purchase ProduceFresh on a limited, as-needed basis, to supplement the capital equipment. Those stores in the enterprise not adopting the capital equipment will continue to use ProduceFresh to meet all their solution needs.





Michael Ashton, Chief Executive Officer of PuriCore, said:



"We are delighted to announce this significant agreement with a leading retailer. Importantly, this contract re-affirms the considerable value realised by customers who use our solution. With the launch of our concentrate product line, we are able to offer our customers expanded options to obtain our solution, but remain able to meet the needs of customers who prefer to purchase equipment based on their level of usage and preference.



"Under this agreement, we will recognise capital equipment revenue and substantial recurring revenue in the form of warranty contracts as well as some continuing consumables revenue from stores remaining on the ProduceFresh platform. Our strategy remains to increase revenue derived from recurring sources, while continuing to offer a capital equipment sale to those customers for whom it is a better fit."





-Ends-